Incannex Healthcare (IXHL) Cash & Equivalents (2020 - 2026)
Incannex Healthcare (IXHL) posted Cash & Equivalents of $74.5 million for Q1 2026, up 8.13% sequentially from $68.9 million in Q4 2025, and up 1010.12% YoY from $6.7 million in Q1 2025.
Incannex Healthcare (IXHL) Cash & Equivalents (2020 - 2026) Analysis & Trends
Incannex Healthcare has reported Cash & Equivalents for 7 years, with the latest figure at $74.5 million in Q1 2026.
- Quarterly Cash & Equivalents rose 1010.12% year-over-year to $74.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.5 million (up 1010.12% YoY) and the FY2025 annual result came in at $15.0 million, up 154.9% from the prior year.
- Cash & Equivalents improved to $74.5 million in Q1 2026 per IXHL's latest filing, from $68.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $74.5 million in Q1 2026 and troughed at $2.1 million in Q4 2024.
- A 5-year average of $28.8 million and a median of $15.0 million in 2025 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 85.58% in 2024, then surged 3184.08% in 2025.
- Over 5 years, Cash & Equivalents stood at $41.4 million in 2022, then tumbled by 64.87% to $14.6 million in 2023, then slumped by 85.58% to $2.1 million in 2024, then soared by 3184.08% to $68.9 million in 2025, then rose by 8.13% to $74.5 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $74.5 million, $68.9 million, and $73.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Incannex Healthcare | 41.74 Mn | 41.74 Mn | - | 74.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.50 Mn |
| Dec 31, 2025 | 68.90 Mn |
| Sep 30, 2025 | 73.30 Mn |
| Jun 30, 2025 | 15.04 Mn |
| Mar 31, 2025 | 6.71 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 3.63 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2024 | 9.31 Mn |
| Dec 31, 2023 | 14.55 Mn |
| Jun 30, 2023 | 22.12 Mn |
| Dec 31, 2022 | 41.42 Mn |
| Jun 30, 2022 | 37.50 Mn |
| Jun 30, 2021 | 9.12 Mn |
| Jun 30, 2020 | 3.60 Mn |